Press releases
Browse US-specific press releases here.
Please visit our Global website for access to global press releases dating back to 2009.
-
GSK and ViiV Healthcare to showcase advances across industry-leading infectious disease portfolio at IDWeek 2024
60 abstracts to be presented across broad and growing portfolio of vaccines and medicines aimed at getting ahead of infectious disease.
Download (PDF, 252.7KB) -
Statement: Zantac (ranitidine) litigation – settlement agreements reached
GSK to resolve 93% (approximately 80,000 cases) of U.S. state court Zantac product liability cases for up to $2.2 billion.
Download (PDF, 130.6KB) -
GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons
GSK will continue to provide data on longer-term follow-up to help recommending bodies determine future revaccination schedules
Download (PDF, 274.3KB) -
GSK announces positive topline data on co-administration of AREXVY and SHINGRIX
GSK announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the safety of AREXVY and SHINGRIX.
Download (PDF, 189.4KB) -
Statement: Zantac (ranitidine) litigation – Russell and Hughes cases
GSK confirmed it has reached two confidential settlements in cases filed in California State Court with Mr. John Russell and Annette Hughes.
Download (PDF, 138.1KB) -
Brooke Shields Partners with GSK to Educate Adults 50 and Older About Their Shingles Risk
GSK’s THRIVE@50+ campaign with Brooke Shields encourages people aged 50 and over to discuss shingles risk and vaccination with their doctor.
Download (PDF, 207.8KB) -
Statement: Zantac (ranitidine) litigation – Dixon case
GSK confirmed it has reached a settlement with Mr. Isaac Dixon, resolving the prostate cancer case filed in Illinois State Court.
Download (PDF, 112.0KB) -
GSK announces positive results from phase III trial of Nucala (mepolizumab) in COPD
GSK announced results of MATINEE, evaluating Nucala, a monoclonal antibody that targets interleukin-5 (IL-5) in adults with COPD.
Download (PDF, 429.6KB) -
Statement: Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Zantac (ranitidine) litigation – Delaware Supreme Court to review Superior Court’s Daubert decision
Download (PDF, 123.0KB) -
Statement: Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Zantac (ranitidine) litigation – Florida State Court Daubert Ruling in Wilson case
Download (PDF, 124.1KB) -
Statement: Zantac (ranitidine) litigation – Joiner case
Jury in Joiner case in Illinois state court finds GSK not liable for plaintiff’s colorectal cancer
Download (PDF, 126.9KB) -
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
Jemperli approval now includes MMRp/MSS tumors, which represent majority of endometrial cancer cases.
Download (PDF, 318.6KB) -
GSK and Flagship Pioneering partner to discover novel medicines and vaccines
Collaboration brings together GSK disease area expertise and development capability with Flagship portfolio of 40+ bioplatform companies
Download (PDF, 130.7KB) -
Statement: Zantac (ranitidine) litigation – Kimbrow case
GSK has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court.
Download (PDF, 110.4KB) -
GSK begins shipping influenza vaccine doses for 2024-25 season
GSK today announced it has started shipping doses of trivalent influenza vaccines to US healthcare providers and pharmacies.
Download (PDF, 230.3KB) -
Statement: US Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices updates recommendations on adult RSV vaccines ahead of the next season
GSK today announced that the US CDC ACIP voted in favor of recommending the routine use of RSV vaccines in all adults aged 75 and above.
Download (PDF, 245.2KB) -
Students nationwide take on the role of space scientists during GSK science in the summer™ in collaboration with the Franklin Institute
Students across the US participate in the free GSK Science in the Summer™ program, partnered with The Franklin Institute.
Download (PDF, 336.0KB) -
Statement: Zantac (ranitidine) litigation – GSK starts process for appeal of recent Delaware Daubert decision
GSK confirms that the Company has taken the first step to seek appeal of the recent Daubert ruling, made by the Delaware Superior Court.
Download (PDF, 132.5KB) -
Statement: Zantac (ranitidine) litigation – Kasza case
GSK welcomes the plaintiff’s voluntary dismissal of the next Zantac case (Kasza).
-
US FDA approves expanded age indication for GSK’s AREXVY, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk
GSK announced FDA approval of AREXVY Vaccine to prevent LRTD in adults aged 50-59 at heightened risk.
Download (PDF, 207.2KB)
